Aspargo expands beyond Spain into Latin America, disrupting

  • Aspargo Laboratories, Inc. and Laboratorios Vanquish, SA jointly launch Sildenafil Oral Spray in Mexico through exclusive licensing and distribution agreements
  • Mexico, Brazil, Argentina and Colombia represent a combined annual market of over $1 billion
  • Aspargo’s Sildenafil oral spray offers a convenient and discreet option for men suffering from OF

ENGLEWOOD CLIFFS, NJ and MEXICO CITY, June 21, 2022 (GLOBE NEWSWIRE) — Aspargo Laboratories, Inc. (“Aspargo”), a private specialty pharmaceutical company focused on the commercialization of innovative drug formulations in tablet form, announced today has entered into an exclusive patent license agreement (the “License”) with LABORATORIOS VANQUISH, SA (“Vanquish”), a leading Mexican pharmaceutical company, to market Sildenafil oral spray in Mexico. Concurrent with the grant of the License, Aspargo and Vanquish have agreed to enter into a distribution, collaboration and profit-sharing agreement for the joint marketing and promotion of Sildenafil Oral Spray in Mexico (the “Distribution Agreement” and , together with the license agreement, the “Agreements”). The agreements allow Aspargo to extend its international commercialization of Sildenafil Oral Spray for the treatment of erectile dysfunction to the Latin American market.

Sildenafil Oral Spray is an oral liquid suspension of sildenafil citrate administered via a spray pump that delivers 12.5mg of sildenafil per push. Aspargo uses an FDA-approved dosing container that delivers the precise amount of Sildenafil Citrate per push based on the patient’s needs. Discreet, easy-to-carry oral spray allows user to customize dosage and prevent pills from splitting or crushing with traditional tablets.

“Expanding our product launch in Mexico allows Aspargo to access the lucrative LATAM markets of Mexico, Brazil, Argentina and Colombia, which represent combined annual sales of more than $1 billion. dollars,” said Michael Demurjian, Chairman and CEO of Aspargo. “This oral spray pocket formulation of Sildenafil Citrate will now provide Mexican men with a convenient and accurate delivery system of a proven erectile dysfunction drug to manage their erectile dysfunction.”

Pursuant to the agreements, Aspargo and Vanquish will jointly market Sildenafil Oral Spray in Mexico and share net income and cash flow from product sales. Farmalider, SA (Madrid, Spain), granting Aspargo patent rights to Sildenafil Oral Spray, will supply the commercial product for the Spanish market under a multi-year supply agreement. The joint venture leverages Aspargo’s proprietary patents, know-how and commercial expertise and Vanquish’s drug logistics, administration, supply chain and distribution services in the Mexican market to maximize product sales.

“At Vanquish, we are committed to making safe and reliable prescription medicines accessible to members of our local communities,” said Aristides Torres, CEO of Vanquish. “Together with Aspargo, we will bring to market an oral spray of the proven drug sildenafil, offering men with erectile dysfunction and their partners a discreet alternative. I am honored to be at the forefront of bringing this drug to Mexico.

Erectile dysfunction is characterized by persistent difficulty in obtaining and maintaining an erection sufficient for sexual intercourse. Although the prevalence of erectile dysfunction has been shown to increase with age, a recent study conducted by the Sexual Medicine and Andrology Unit of the University of Florence, Italy, showed that erectile dysfunction Erectile dysfunction in younger men is likely to be overlooked and dismissed without proper medical evaluation. .

About Aspargo Laboratories, Inc.

Aspargo Laboratories, Inc., located in Englewood Cliffs, New Jersey, is a commercial-stage specialty pharmaceutical company. Aspargo’s current goal is to market an oral spray formulation of sildenafil citrate, the active ingredient in Viagra®. Aspargo is the US and international patent holder of the Sildenafil oral spray from Farmalider, SA of Madrid, Spain ( For more information, please visit our website at

About Vanquish Laboratories

Laboratorios Vanquish is a private pharmaceutical company headquartered in Mexico City, Mexico. The company is engaged in the development, manufacture and marketing of drugs and medical devices, primarily for the institutional market. For more information, please visit our website at

Aspargo Laboratories, Inc.
(201) 408-4831
[email protected]


Comments are closed.